DA Berry

I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

AD Barker, C C Sigman, Kelloff Gj et al. · Clinical Pharmacology & Therapeutics · 2009 · 740 citations

Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)

W. M. Sikov, DA Berry, CM Perou et al. · Cancer Research · 2016 · 86 citations

Breast Oncology, Cancer Epidemiology, Overall Survival +14

Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)

W. M. Sikov, DA Berry, CM Perou et al. · Cancer Research · 2013 · 54 citations

Breast Oncology, Pathologic Complete Response, Pathology +17

The Signature Program: Bringing the Protocol to the Patient

BP Kang, Eric D. Slosberg, Susan Snodgrass et al. · Clinical Pharmacology & Therapeutics · 2015 · 26 citations · Full text

Pathology, Protocol Compliance, Early-phase Clinical Development +21

Abstract GS3-08: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL

Douglas Yee, A. DeMichele, Claudine Isaacs et al. · Cancer Research · 2018 · 16 citations

Breast Oncology, Disease Progression, Cancer Management +19